Wockhardt exits US generics biz to focus on drug discovery

Wockhardt is set to exit its loss-making US generics business to prioritize innovation, focusing on new antibiotic drug discovery and its biologics portfolio in insulin. The company has initiated voluntary liquidation for its US subsidiaries under Chapter 7 of the US Bankruptcy Code. This strategic shift allows Wockhardt to concentrate on high-impact areas and long-term value creation through scientific advancements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rc26b7Z
via IFTTT